Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL-IMPACT: Vericiguat in Obese Black Individuals with Insulin Resistance
NCT06320951Phase 2Not yet recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vericiguat in insulin resistance (IR), obesity, sponsored by University of Alabama at Birmingham. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
vericiguat
03
Conditions
insulin resistance (IR)obesity
Beyond the preview
Go deeper on NCT06320951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06320951.